Diane Havlir, MD

Professor of Medicine
M_MED-ZSFG-AIDS
[email protected]

Diane Havlir, MD is a member of the National Academy of Medicine; Professor of Medicine at UCSF; and Chief of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General, home to world-renowned HIV research and the Ward 86 clinical program. She serves as Associate Chair of Clinical Research in the Department of Medicine, as well as Director of the UCSF AIDS Research Institute (ARI) as the Robert L. Weiss Memorial Chair for HIV/AIDS Research. Dr. Havlir is the Principal Investigator of the Sustainable East Africa Research in Community Health (SEARCH) Collaboration.

Dr. Havlir was a resident at UCSF when the AIDS epidemic emerged in the 1980s and has since devoted her career to caring for people with HIV and advancing ground-breaking research. Her seminal research helped define the first medicine combinations to transform HIV from a uniformly fatal to a chronic disease. A long-standing NIH-funded investigator, she has authored over 400 publications, including in The New England Journal of Medicine, JAMA, and other high-impact journals. She co-founded and continues to co-chair San Francisco Getting to Zero (GTZ), a citywide initiative to eliminate new HIV infections and deaths.

Globally, Dr. Havlir has been active in leadership roles with the World Health Organization (WHO), including chairing the global HIV Drug Resistance Surveillance Network and the HIV–TB Working Group. She co-chaired the WHO’s global guidelines on HIV treatment and prevention, and she chaired the UNAIDS Scientific and Technical Advisory Committee, which provides high-level guidance on global strategies to combat the HIV/AIDS pandemic.

The overall goal of Dr. Havlir’s research is to develop and test strategies to prevent and treat HIV and other global infectious disease pandemics. Antiretroviral medicines—for prevention (PrEP/PEP) and treatment (ART)—are among the greatest successes of modern medicine, yet gaps persist globally, hindering progress in eliminating HIV and its complications such as tuberculosis (TB). In the first SEARCH study, an NIH-funded 320,000-person cluster-randomized study in rural East Africa, Dr. Havlir’s team showed that a multi-disease, patient-centered approach to HIV testing and treatment reduced HIV incidence, HIV-associated tuberculosis and HIV-associated mortality, while improving population-level control of hypertension. Dr. Havlir continues to advance her goal of accelerating the end of AIDS through the SEARCH-Sapphire study, testing an innovative “Community Precision Health” strategy that uses a multi-disease approach to incorporate AI and machine learning into delivery systems to improve the effectiveness and efficiency of healthcare.

During the COVID-19 pandemic, Dr. Havlir co-founded Unidos en Salud, a city–community–academic partnership with the Latino Task Force, Chan Zuckerberg Biohub, the San Francisco Department of Public Health, and BayPLS. The collaboration delivered low-barrier test-and-respond and vaccine services to thousands of local residents, generating real-time epidemiologic data for the Mission District of San Francisco.

Publications

Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.

Communications medicine

Phillips AN, Bershteyn A, Revill P, Bansi-Matharu L, Kripke K, Boily MC, Martin-Hughes R, Johnson LF, Mukandavire Z, Jamieson L, Meyer-Rath G, Hallett TB, Ten Brink D, Kelly SL, Nichols BE, Bendavid E, Mudimu E, Taramusi I, Smith J, Dalal S, Baggaley R, Crowley S, Terris-Prestholt F, Godfrey-Faussett P, Mukui I, Jahn A, Case KK, Havlir D, Petersen M, Kamya M, Koss CA, Balzer LB, Apollo T, Chidarikire T, Mellors JW, Parikh UM, Godfrey C, Cambiano V, HIV Modelling Consortium

Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco.

The American journal of tropical medicine and hygiene

Peng J, Liu J, Mann SA, Mitchell AM, Laurie MT, Sunshine S, Pilarowski G, Ayscue P, Kistler A, Vanaerschot M, Li LM, McGeever A, Chow ED, Marquez C, Nakamura R, Rubio L, Chamie G, Jones D, Jacobo J, Rojas S, Rojas S, Tulier-Laiwa V, Black D, Martinez J, Naso J, Schwab J, Petersen M, Havlir D, DeRisi J, IDseq Team

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19.

BMJ open

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Le Voyer T, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ, UCSF COMET consortium

Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19.

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Voyer TL, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, UCSF COMET consortium , Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ

Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.

Communications medicine

Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, Atukunda M, Mwangwa F, Peng J, Mwinike Y, Owaraganise A, Chamie G, Jain V, Sang N, Olilo W, Brown LB, Marquez C, Zhang K, Ruel TD, Camlin CS, Rooney JF, Black D, Clark TD, Gandhi M, Cohen CR, Bukusi EA, Petersen ML, Kamya MR, Havlir DV

HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.

M_MED-CORE-PULM

Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, Kabami J, Sang N, Liegler T, Chamie G, Camlin CS, Jain V, Kadede K, Atukunda M, Ruel T, Shade SB, Ssemmondo E, Byonanebye DM, Mwangwa F, Owaraganise A, Olilo W, Black D, Snyman K, Burger R, Getahun M, Achando J, Awuonda B, Nakato H, Kironde J, Okiror S, Thirumurthy H, Koss C, Brown L, Marquez C, Schwab J, Lavoy G, Plenty A, Mugoma Wafula E, Omanya P, Chen YH, Rooney JF, Bacon M, van der Laan M, Cohen CR, Bukusi E, Kamya MR, Petersen M

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

M_PEDS-INFECTIOUS DISEASE

Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C

Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

M_MED-CORE-PULM

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Essential Strategies for Leveraging AI in the Global HIV Response

Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.

M_MED-CORE-PULM

Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I

Prevention of HIV-1 infection with early antiretroviral therapy.

M_MED-CORE-PULM

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR